REFERENCES
- Shipp M., Mauch P.M., Harris N.L. Non-Hodgkin's Lymphomas. Cancer Principles and Practice of Oncology, V.T. DeVita, Jr., S. Hellman, S.A. Rosenberg. 5th Ed., Lippincott, Philadelphia, PA 1996; 2165–2220
- Bseiso A.W., McLaughlin P. The Indolent Lymphomas. Medical Oncology, R. Pazdur. 2nd Ed., PRR, Huntington, NY 1995; 73–97
- Fisher R.I., Gaynor E.R., Dahlberg S., , et al. Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma. N. Engl. J. Med. 1993; 328: 1002
- Rowinsky E.K., Grochow L.B., Hendricks C.B., , et al. Phase I and Pharmacologic Study of Topotecan: A Novel Topoisomerase I Inhibitor. J. Clin. Oncol. 1992; 10: 647–656
- D'Arpa P., Liu L.F. Topoisomerase Targeting Antitumor Drugs. Biochim. Biophys. Acta 1989; 989: 163–177
- Wang J.C. DNA Topoisomerase. Annu. Rev. Biochem. 1996; 65: 635–692
- Hsiang Y.H., Liu L.F., Wall M., , et al. DNA Topoisomerase I Mediated DNA Cleavage and Cytotoxicity of Camptothecin Analogues. Cancer Res. 1989; 49: 4835–4839
- Topotecan Hydrochloride. SKF-104864-A. Investigator Brochure 1: 1998.
- Rowinsky E.K., Adjei A., Ross C., , et al. Phase I and Pharmacodynamic Study of the Topoisomerase I Inhibitor Topotecan in Patients with Refractory Acute Leukemia. J. Clin. Oncol. 1994; 12: 2193–2203
- Schuller J.H., Kim R., Hutson P., , et al. Phase II Study of Topotecan in Patients with Extensive Small Cell Carcinoma of the Lung: An Eastern Cooperative Group Study. J. Clin. Oncol. 1996; 14: 2345–2352
- Creemers G.J., Bolis G., Gore M., , et al. Topotecan, an Active Drug in the Second Line Treatment of Epithelial Ovarian Cancer. Results of a Large European Phase II Study. J. Clin. Oncol. 1996; 14: 3056–3061
- Okno R., Okuda K., Masaoka T., , et al. An Early Phase II Study of CPT-11: A New Derivative of Camptothecin in the Treatment of Leukemia and Lymphoma. J. Clin. Oncol. 1990; 8: 1907–1912
- Summary and Description of a Working Formulation for Clinical Usage. Cancer 1982; 49: 2112–2135
- Subramanian D., Kraut E., Staubus A., , et al. Analysis of Topoisomerase I/DNA Complexes in Patients Administered Topotecan. Cancer Res. 1995; 55: 2097–2103
- Simon R. Optimal Two-Stage Designs for Phase II Clinical Trials. Cont. Clin. Trials 1989; 10: 1–10
- Shipp M.A. Prognostic Factors in Aggressive Non-Hodgkin's Lymphoma—Who Has High Risk Disease?. Blood 1994; 83: 1165
- Potmesil M. Camptothecins: From Bench Research to Hospital Wards. Cancer Res. 1994; 54: 1431–1439
- Pommier Y., Leteurtre F., Fesen M.R., , et al. Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors. Cancer Invest. 1994; 12: 530–542
- Potmesil M., Hsiang Y.H., Liu L.F., , et al. Resistance of Human Leukemic and Normal Lymphocytes to Drug-Induced DNA Cleavage and Low Levels of DNA Topoisomerase II. Cancer Res. 1988; 48: 3537–3543
- Potmesil M., Hsiang Y.H., Liu L.F., , et al. Topoisomerase I and Topoisomerase II Levels in High and Low Grade Lymphomas. Proc. Am. Assoc. Cancer Res. 1988; 29: 176
- Preti H.A., Plunkett W., Sarris A.H., , et al. Preliminary Results of a Phase II Trial of Topotecan in Patients with Relapsing Lymphoma. Blood 1995; 86: 3268
- Ota K., Ohno R., Shirakawa S., , et al. Late Phase II Clinical Study of Irinotecan Hydrochoride (CPT-11) in the Treatment of Malignant Lymphoma and Acute Leukemia. The CPT-11 Research Group for Hematological Malignancies, Gan Kagaku Ryoho 1994; 21: 1047–1055
- Wilson W.H., Little R., Pearson D., , et al. Phase II and Dose Escalation with or without Granulocyte Stimulating Factor Study of 9-Aminocamptothecin in Relapsed and Refractory Lymphomas. J. Clin. Oncol. 1998; 16: 2345–2351
- Subramanian D., Rosenstein B.S., Muller M.T. Ultraviolet Induced DNA Damage Stimulates Topoisomerase I DNA Complex Formation In Vivo Possible Relationship with DNA Repair. Cancer Res. 1998; 58: 976–984